• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

With No­var­tis clos­ing in, Re­gen­eron scraps Eylea com­bo drug in a ma­jor set­back

8 years ago
R&D

Flag­ship, Arch cut their loss­es, qui­et­ly shut­ter En­sem­ble Ther­a­peu­tics as pipeline plans fiz­zle out

8 years ago
Startups

Mer­ck blue­prints $1.3B re­search hub in a post-Brex­it Lon­don, with 950 staffers

8 years ago
R&D
Pharma

Te­va R&D chief out as new CEO picks up the ax and aims at deep cuts to res­cue a fal­ter­ing bio­phar­ma — re­port

8 years ago
R&D
Pharma

The 10 most pop­u­lar sto­ries in End­points News — so far in 2017

8 years ago
Editor's note

In­nate shares crushed on sec­ond big set­back for Bris­tol-My­ers part­nered lir­ilum­ab

8 years ago
R&D

Open plan de­signs: The good, the bad and the ug­ly; Fre­se­nius adding 400-plus staffers

8 years ago
News Briefing

Un­der pres­sure from copy­cats, Roche sues Pfiz­er over Her­ceptin ri­val

8 years ago
Pharma

Study repli­cates piv­otal tri­al re­sults us­ing 're­al world ev­i­dence'

8 years ago
Outsourcing

#ASH17: Late break­er from Ab­b­Vie, Roche high­lights a block­buster break­out op­por­tu­ni­ty for Ven­clex­ta in CLL

8 years ago
R&D

Six top biotech VCs take a look at the lat­est trends, and of­fer their thoughts on 2018

8 years ago
People
Financing

With bil­lions rid­ing on their suc­cess, GSK bags quick OK for its two-drug HIV com­bo Ju­lu­ca

8 years ago
Pharma

Jeff Capel­lo joins Bio­gen as CFO; Tesaro en­ters $500M loan agree­ment; Palatin li­cens­es fe­male li­bido drug to Ko­re­a's ...

8 years ago
News Briefing

Build­ing on im­pres­sive da­ta, No­vo Nordisk maps big PhI­II obe­si­ty pro­gram for block­buster hope­ful semaglu­tide

8 years ago
R&D

French up­start Step Phar­ma rais­es €8.6M, tak­ing im­muno­sup­pres­sive drugs to the clin­ic

8 years ago
Financing

Cy­to­ki­net­ics ax­es lead drug af­ter it im­plodes in a PhI­II mus­cle tri­al for ALS, shares crater

8 years ago
R&D

Arde­lyx scraps PhI­II drug af­ter re­searchers raise a safe­ty is­sue for hy­per­kalemia pa­tients

8 years ago
R&D

Stan­ford tri­al points to a new CAR-T drug, spot­light­ing a fresh tar­get for next-gen cell ther­a­pies

8 years ago
Discovery

Af­ter un­ex­pect­ed tie, Am­s­ter­dam wins 'coin toss' for new EMA HQ

8 years ago
Pharma

Pro­men­tis clos­es $26M round and en­ters clin­ic; Pelle­Phar­ma gets break­through/or­phan sta­tus; Shire ap­points Dit­trich ...

8 years ago
News Briefing

The top 10 hit pa­rade of bio­phar­ma li­cens­ing deals for 2014-2017

8 years ago
Pharma

Bay­er AG taps Pep­tiDream in bil­lion-dol­lar deal

8 years ago
R&D
Pharma

FDA adds ‘break­through’ sta­tus for Al­ny­lam as patisir­an starts its vic­to­ry lap at the agency

8 years ago
Pharma

Acor­da writes off $363M drug, ax­ing PhI­II Parkin­son’s drug in the wake of 5 pa­tient deaths

8 years ago
R&D
First page Previous page 1067106810691070107110721073 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.